Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GB261 monotherapy in relapsed or refractory B-cell non-Hodgkin lymphoma and CLL/SLL
CTR20221794Phase 2Active
- Sponsor
- Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology
- Start
- Jul 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GB261 in mature B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology. Started Jul 2022; status: active.
02
Drugs
GB261
03
Conditions
mature B-cell lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20221794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221794.